Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

6.69USD
20 Jul 2018
Change (% chg)

$0.43 (+6.87%)
Prev Close
$6.26
Open
$6.87
Day's High
$7.25
Day's Low
$6.43
Volume
55,392
Avg. Vol
15,872
52-wk High
$20.50
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Cellectar Reports Positive Phase 2 Interim Data For CLR 131 In Relapsed/Refractory DLBCL Patients
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS POSITIVE PHASE 2 INTERIM DATA FOR CLR 131 IN RELAPSED/REFRACTORY DLBCL PATIENTS.CELLECTAR BIOSCIENCES - AS A RESULT OF FAVORABLE OUTCOMES, CO HAS EXPANDED COHORT TO INCLUDE UP TO 30 ADDITIONAL PATIENTS.CELLECTAR BIOSCIENCES INC - OBSERVED RESPONSES FROM STUDY TO DATE SHOW OVERALL TUMOR REDUCTION RANGED FROM 60% TO GREATER THAN 90%.CELLECTAR BIOSCIENCES INC - INTERIM DATA FROM STUDY SHOW A 33% OVERALL RESPONSE RATE AND A 50% CLINICAL BENEFIT RESPONSE.  Full Article

Cellectar Announces 1-For-10 Reverse Stock Split
Friday, 13 Jul 2018 

July 13 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.CELLECTAR BIOSCIENCES INC - ANNOUNCES A 1-FOR-10 REVERSE SPLIT OF ITS COMMON STOCK, EFFECTIVE AT CLOSE OF BUSINESS TODAY.  Full Article

Cellectar Granted Orphan Drug Designation For CLR 131
Wednesday, 9 May 2018 

May 9 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA.  Full Article

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences says USPTO grants patent for Paclitaxel PDC
Monday, 12 Dec 2016 

Cellectar Biosciences Inc : Cellectar Biosciences announces USPTO grants patent for Paclitaxel PDC; provides additional patent protection for select solid tumors through 2035 .Cellectar Biosciences - plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017.  Full Article

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage: